Pfizer applies for COVID-19 vaccine approval for 5-11 year olds in Japan

Tribune Web Desk

Updated At : 07:35 PM Nov 10, 2021 IST

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits

Yearly Premium ₹999 ₹349/Year

Yearly Premium $49 $24.99/Year

TOKYO, November 10

Pfizer Inc has applied for approval from Japan’s health ministry to use COVID-19 vaccines on children aged 5 to 11, it said in a statement released on Wednesday.

Pfizer’s Comirnaty vaccine, developed in partnership with BioNTech, was the first COVID-19 vaccine approved for Japan’s general public in February. COVID-19 vaccines developed by Moderna and AstraZeneca have since been approved.

Pfizer’s vaccine is currently being offered to those aged 12 and above. If approved by the health ministry, it will be the first to be administered to children under 11 in Japan.

About 74% of the population is now fully vaccinated, according to broadcaster NHK, and the government is widely expected to start administering booster shots by year-end. Reuters

The Tribune, now published from Chandigarh, started publication on February 2, 1881, in Lahore (now in Pakistan). It was started by Sardar Dyal Singh Majithia, a public-spirited philanthropist, and is run by a trust comprising five eminent persons as trustees.

The Tribune, the largest selling English daily in North India, publishes news and views without any bias or prejudice of any kind. Restraint and moderation, rather than agitational language and partisanship, are the hallmarks of the newspaper. It is an independent newspaper in the real sense of the term.

The Tribune has two sister publications, Punjabi Tribune (in Punjabi) and Dainik Tribune (in Hindi).

Remembering Sardar Dyal Singh Majithia

Designed and developed by : SORTD

Unlock Exclusive Insights with The Tribune Premium

Suggested Articles